16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting P4HA1 could help treat triple-negative breast cancer (TNBC). In tumor samples from TNBC patients, levels of P4HA1 protein were higher than in samples from estrogen...
18:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest PEGylated ARG1 and dichloroacetate could help treat breast cancer. In a human triple-negative breast cancer (TNBC) and a human estrogen receptor-positive breast cancer cell line, the...
19:18 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

Private sharing

A new cryptographic computational protocol from the Massachusetts Institute of Technology will allow drug companies to pool data for predictive modeling of drug-target interactions without revealing the underlying drugs, targets or observed interactions. The method...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast Cancer Patient sample, cell culture and mouse studies suggest inhibiting ANKLE2 could help treat breast cancer. In breast cancer patients, high tumor levels of ANKLE2 were associated with disease progression and poor overall...
18:19 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Arvinas raises $120M in IPO

Arvinas Inc. (NASDAQ:ARVN) raised $120 million late Sept. 26 through the sale of 7.5 million shares at $16 in its bumped-up IPO. The price, at the top of its proposed $14-$16 range, values the company...
15:34 , Sep 27, 2018 |  BC Extra  |  Financial News

Trio of IPOs price: Arvinas, Sutro, Urovant

Arvinas Inc. (NASDAQ:ARVN), Sutro Biopharma Inc. (NASDAQ:STRO) and Urovant Sciences Ltd. (NASDAQ:UROV) each priced IPOs late Wednesday, raising a total of $345 million. On Thursday, Arvinas gained $0.05 to $16, and Sutro was up $0.20...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
18:31 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
19:59 , Aug 30, 2018 |  BC Extra  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on...
21:36 , Aug 23, 2018 |  BC Extra  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...